Almirall, InDex deal

InDex granted Almirall rights to develop and commercialize Kappaproct in Europe. InDex is eligible for up €20 million ($27.5 million) in upfront and "near term" milestone payments and up to €80 million ($110.1 million) in regulatory and sales milestones, plus double-digit royalties. InDex will be responsible for clinical development, and Almirall will be responsible for filing the MAA. InDex said it expects Almirall to submit the application in 2017 if two Phase III studies are needed. InDex also said it plans to submit a regulatory filing in the U.S. in 2017. ...